Hypothalamic brain-derived neurotrophic factor (BDNF) is a key element in the regulation of energy balance. Here we investigated the therapeutic efficacy of BDNF by gene transfer in mouse models of obesity and diabetes. Gene transfer of BDNF led to marked weight loss and alleviation of obesityassociated insulin resistance. To facilitate clinical translation and ensure that BDNF protein expression was appropriately decreased as weight loss progressed, thus preventing cachexia, we developed a molecular autoregulatory system involving a single recombinant adeno-associated virus vector harboring two expression cassettes, one constitutively driving BDNF and the other driving a specific microRNA targeting BDNF. The microRNA element was controlled by a promoter (that controlling the Agrp gene encoding agouti-related peptide) responsive to BDNF-induced physiological changes. Hence, as body weight decreased and agouti-related protein is induced, microRNA expression was activated, inhibiting transgene expression. In contrast to the progressive weight loss associated with a nonregulated approach, this microRNA-approach led to a sustainable plateau of body weight after notable weight loss was achieved. This strategy mimics the body's endogenous physiological feedback mechanisms, thereby resetting the hypothalamic set point to reverse obesity and metabolic syndrome.
Hypothalamic brain-derived neurotrophic factor (BDNF) is a key element in the regulation of energy balance. Here we investigated the therapeutic efficacy of BDNF by gene transfer in mouse models of obesity and diabetes. Gene transfer of BDNF led to marked weight loss and alleviation of obesityassociated insulin resistance. To facilitate clinical translation and ensure that BDNF protein expression was appropriately decreased as weight loss progressed, thus preventing cachexia, we developed a molecular autoregulatory system involving a single recombinant adeno-associated virus vector harboring two expression cassettes, one constitutively driving BDNF and the other driving a specific microRNA targeting BDNF. The microRNA element was controlled by a promoter (that controlling the Agrp gene encoding agouti-related peptide) responsive to BDNF-induced physiological changes. Hence, as body weight decreased and agouti-related protein is induced, microRNA expression was activated, inhibiting transgene expression. In contrast to the progressive weight loss associated with a nonregulated approach, this microRNA-approach led to a sustainable plateau of body weight after notable weight loss was achieved. This strategy mimics the body's endogenous physiological feedback mechanisms, thereby resetting the hypothalamic set point to reverse obesity and metabolic syndrome.
Obesity confers considerable risk for diabetes, cardiovascular disease, stroke and some cancers 1, 2 . Obesity and the metabolic syndrome are increasing rapidly worldwide with substantial morbidity and mortality and socioeconomic burden 3 . Lifestyle modifications such as exercise and diet as well as approved drugs have limited efficacy. Bariatric surgery can lead to weight loss at the cost of substantial morbidity, underscoring the need for a safer and more effective approach.
To identify potential molecular therapeutic candidates, we used an environmental paradigm. In our previous studies, we found that physically and socially more complex housing leads to increased neurogenesis, improved learning and memory and resistance to insults [4] [5] [6] . Moreover, although mice housed in such enriched environments are fed ad libitum on identical diets, they gain less weight than do control animals living in standard housing, with an improved metabolic profile and insulin sensitivity. To further characterize this phenotype, we focused on potential regulators in the hypothalamic arcuate nucleus, a brain region crucial to energy balance. Amongst a number of genes screened, we observed a consistent upregulation in Bdnf expression at 2, 4 and 9 weeks of enrichment (L.C., E.-J.D.L., V. Riban, M.C.C., C.W., B. Lin et al., unpublished data).
BDNF has previously been identified as a key component of the hypothalamic pathway that controls body weight and energy homeostasis 7 . Obese phenotypes are found in Bdnf-heterozygous mice 8 , a conditional knockout model 9 and focal hypothalamic deletion in adult mice 10 . This mature-onset obesity is associated with hyperphagia, hyperleptinemia, hyperinsulinemia and hyperglycemia. Moreover, in humans similar symptoms are associated with the functional loss of one copy of the BDNF gene 11 and with a de novo mutation in the BDNF receptor Ntrk2 gene 12 . Both peripheral and central administration of BDNF decreases food intake, increases energy expenditure and leads to weight loss 13, 14 . Moreover, acute intracerebroventricular administration of BDNF ameliorates hyperinsulinemia and hyperglycemia in diabetic db/db mice 15 . To determine whether BDNF somatic cell gene transfer can replicate the lean body weight and improved metabolic profile associated with an enriched environment, we used recombinant adeno-associated virus (rAAV) to focally overexpress BDNF in the hypothalamus of normal-weight mice on a normal chow diet (NCD). In addition, we looked at the therapeutic potential of this approach in a diet-induced obesity (DIO) model involving a high-fat diet (HFD). Furthermore, we developed a physiological autoregulatory gene expression system and assessed its efficacy in leptin receptor-deficient db/db mice, a genetic model of diabetes and obesity.
RESULTS
Hypothalamic gene transfer of BDNF in normal mice fed a NCD We delivered hemagglutinin (HA)-tagged human BDNF to the hypothalamus bilaterally via rAAV, using GFP as a control. In a subset of mice, we determined gene transfer efficacy by HA immunofluorescence and GFP fluorescence for the respective vectors, with expression observed in the arcuate nucleus and ventromedial hypothalamus (Fig. 1a,b) . Consistent with the use of a constitutive promoter, we observed expression in the majority of neurons in the targeted region, including in arcuate agouti-related protein (AgRP) and neuropeptide Y (NPY) coexpressing neurons (Fig. 1c) . We observed an initial surgery-associated weight loss in both groups, but GFP-expressing mice quickly recovered and then regained weight on their presurgery trajectory (Fig. 1d) . In contrast, BDNF-expressing mice continued to lose weight throughout the course of the experiment (Fig. 1d) . By one month after injection, the weight of BDNF-expressing mice had decreased by 3.66 ± 0.27 g, whereas the weight of GFP-expressing mice had increased by 1.91 ± 0.37 g. There was no significant change in food consumption ( Supplementary Fig. 1a online) . Adiposity was greatly reduced in BDNF-expressing mice, as indicated by a 92% reduction in the weight of the perigonadal fat pad at 50 d after injection (Fig. 1e) .
BDNF expression led to a sharp decrease in leptin abundance (12.2% ± 2.6% of GFP-expresssing mice, P o 0.001) and insulin (18.0% ± 2.3% of GFP, P o 0.001). Both leptin and insulin concentrations are known to correlate with fat mass 16 . Moreover expression of adiponectin, a major adipokine with a role in regulating insulin sensitivity and inhibiting appetite 17 , was markedly increased in BDNF-expressing mice, whereas cholesterol, triglyceride and insulinlike growth factor-1 concentrations were all reduced (Supplementary Table 1 online) .
We used real-time quantitative PCR to examine hypothalamic expression of genes involved in energy homeostasis. Agrp and Npy, which encode two orexigenic peptide hormones, were upregulated 15.11 ± 1.44-fold and 7.55 ± 1.04-fold in BDNF-expressing, compared to GFP-expressing, mice, respectively (Fig. 1f) , consistent with a compensatory response to the weight loss and fat depletion 18 . Mc4r (encoding melanocortin-4 receptor), proposed to be upstream of both BDNF and a major pathway shared by leptin, insulin and other anorexic signals 9 , was upregulated significantly, whereas expression levels of the additional anorexigenic molecules Cartpt (encoding CART prepropeptide) and Pomc (encoding proopiomelanocortin) were not changed (Fig. 1f) . Expression of the BDNF receptor Ntrk2 was increased, indicating positive feedback (Fig. 1f) . Insulin receptor (Insr) expression was also upregulated, whereas expression of the leptin receptor long form (Lepr) was not changed (Fig. 1f) . Expression of Trh (encoding thyrotropin-releasing hormone) and Crh (encoding corticotropin-releasing hormone) was increased in BDNF-expressing mice (Fig. 1f) .
BDNF gene transfer prevents DIO Chronic consumption of a HFD contributes to obesity in experimental animals and humans. We used C57BL/6 mice, a strain prone to DIO, to assess the therapeutic efficacy of hypothalamic BDNF gene transfer 19 . Given the potency of the rAAV-BDNF vector observed in normal mice, we decreased the dose (from 3 Â 10 9 genomic titer per site to 2 Â 10 9 genomic titer per site) and used older (18 weeks) mice. We also used a destabilized yellow fluorescent protein (YFP) as our control, as GFP has been associated with nonspecific toxic effects. Ten days after surgery, we switched the mice to a 45% HFD. The weight gain of YFP-expressing mice, which acted as our control treatment group, accelerated, whereas BDNF-expressing mice maintained a stable weight (Fig. 2a) . By 72 d after surgery, YFP-expressing mice had gained 13.78 ± 1.88 g on the HFD, whereas BDNF-expressing mice lost 2.80 ± 0.71 g with no change in food consumption ( Supplementary Fig. 1b) . YFP-expressing mice developed abdominal obesity with the weight of perigonadal fat pads increased by 4.5-fold compared to NCD controls (data not shown). In contrast, the perigonadal pad weight of BDNF-expressing mice was only 14.2 ± 3.1% that of the YFP-expressing mice. The weight of subcutaneous fat was also greatly less (Fig. 2b,c) , and the pericardial fat observed in YFP-expressing mice was completely absent in the BDNF-expressing mice (Fig. 2b) . Moreover, H&E staining revealed an 85.7 ± 1.1% smaller adipocyte size in BDNF-expressing mice (Fig. 2d) .
DIO was associated with hyperinsulinemia, hyperleptinemia, hyperglycemia and dyslipidemia, with BDNF completely preventing this metabolic profile (Supplementary Table 1 ). The lower circulating leptin concentrations were not solely due to the smaller fat mass. When leptin concentrations were standardized to the perigonadal fat pad weight, BDNF-expressing mice still showed a significant decrease (YFP-expressing mice, 7.347 ± 0.612 pg ml À1 g À1 ; BDNF-expressing mice, 3.735 ± 0.798 pg ml À1 g À1 ; P ¼ 0.003). In contrast, adiponectin showed a greater than 14-fold higher level when its concentration was corrected to fat mass (YFP-expressing mice, 1.624 ± 0.314 ng ml À1 g À1 ; BDNF-expressing mice, 24.030 ± 5.540 ng ml À1 g À1 ; P ¼ 0.005), indicating that BDNF expression influenced adipocyte autonomous 
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leptin and adiponectin secretion. In addition, the insulin insensitivity and glucose intolerance observed in YFP-expressing obese mice were greatly improved in BDNF-expressing mice ( Fig. 2 and Supplementary Fig. 1c ).
HFD feeding led to liver steatosis in obese YFP-expressing mice, as characterized by pale macroscopic enlargement ( Fig. 2b) and excessive fat accumulation observed in oil red O-stained ( Fig. 2e ) and H&E-stained ( Fig. 2f) sections. BDNF expression prevented the liver steatosis ( Fig. 2e,f) , with the liver weight being 45% that of the YFP-expressing mice (BDNF-expressing mice, 1.18 ± 0.05 g; YFPexpressing mice, 2.61 ± 0.29 g; P ¼ 0.001).
We profiled the expression of genes involved in lipid metabolism and mitochondrial activity in both white adipose tissue (WAT, Fig. 3a ) and brown adipose tissue (data not shown) 20 . In WAT, Ppargc1a, encoding a cofactor controlling mitochondrial biogenesis 21 , was upregulated 9.8 ± 2.2-fold in BDNF-expressing mice, whereas the expression of cytochrome c (Cycs) was increased 3.2 ± 0.5-fold compared to the obese control mice. Uncoupling proteins (UCP) are a family of proteins involved in the regulation of lipid oxidation as well as the regulation of energy expenditure 22 . The expression of Ucp3 was increased 6.8 ± 1.9-fold in WAT from mice expressing BDNF, suggesting a possible increase in energy expenditure of WAT. Moreover, Lep (encoding leptin) expression was decreased by 62.0% ± 7.9%, whereas Adipoq (encoding adiponectin) expression was increased by 6.1 ± 1.9-fold, consistent with the observed weight loss 23 . Lep expression was also decreased by 68.5% ± 14.3% in BDNF brown adipose tissue whereas no other genes screened were significantly changed.
BDNF treatment significantly suppressed lipogenic gene expression in liver, decreasing Fasn (encoding fatty acid synthase) expression by 43.1% ± 17.5%, Gpam (encoding mitochondrial glycerol-3-phosphate acyltransferase) by 66.4% ± 4.2% and Scd1 (encoding stearoyl-CoA desaturase) by 37.8% ± 10.9%. Its effects on lipolytic genes were less marked, with a decrease in Acox1 (encoding acyl-coenzyme A oxidase-1, palmitoyl) expression but no change in Cpt1a (encoding carnitine palmitoyltransferase 1A) expression, although both are involved in fatty acid oxidation 24 (Fig. 3b) . Expression of Pparg, an adipocytespecific peroxisome proliferator-activated receptor isoform and a type 2 diabetes marker, was decreased by 99.6% ± 0.1% in the liver of BDNFtreated mice, consistent with the absence of fatty infiltration 25 . Expression of Ucp2, a mitochondrial inner-membrane protein that uncouples ATP synthesis and negatively regulates reactive oxygen species production 26 , was significantly upregulated by 3.39 ± 0.86-fold in the liver of BDNF-treated mice, which may serve a protective role when hepatocytes are exposed to metabolic stress such as highfat feeding. We also profiled hypothalamic gene expression in 
BDNF-expressing mice on a HFD and observed a similar pattern of changes as BDNF-expressing mice fed with a NCD except that Cartpt was upregulated approximately threefold in the HFD condition ( Fig. 1f versus Fig. 3c ).
Transgene expression in the hypothalamus was maintained throughout the duration of the experiment, with BDNF concentrations of 5541.4 ± 738.4 pg mg À1 in BDNF-expressing mice compared to 87.6 ± 11.2 pg mg À1 in YFP-expressing mice, P o 0.001. Moreover, histological examination of hypothalamic sections showed a lack of cytotoxicity with no cell loss (as determined by Nissl staining, Supplementary Fig. 2a online) , no gliosis (as determined by glial fibrillary acidic protein staining, Supplementary Fig. 2b ) and no apoptosis (TUNEL assay, Supplementary Fig. 2d ).
An autoregulatory BDNF vector in diabetic db /db mice Gene therapy dose titration in humans is difficult, particularly in a clinical setting where diet is not tightly controlled. We, therefore, aimed to improve the safety of the approach and develop a vector that could be considered for clinical translation. Ideally, we would like to tightly couple transgene expression to the physiological changes induced by the expression of the introduced therapeutic gene. Of the hypothalamic genes profiled in BDNF-expressing mice, Agrp was the most robustly upregulated, with 15.1-fold and 16.2-fold increases in expression in mice on NCD and HFD, respectively, (Figs. 1f and 3c) consistent with the observed weight loss and particularly the decrease in body fat mass 27 . We amplified two human AGRP promoter fragments of different lengths, each containing the hypothalamusspecific exon 28 . We coupled the AGRP promoter fragments to a luciferase reporter gene and packaged these cassettes into rAAV vectors. We injected these AGRP promoter-driven luciferase vectors into the hypothalamus together with the BDNF vector to induce weight loss and compared luciferase activity with YFP controls. The 484-base pair (bp) fragment promoter (termed AGRP484) showed better inducibility than the 814-bp fragment. The induction of AGRP484 was 2.66 ± 0.57-fold, whereas the induction of AGRP814 was 1.32 ± 0.38-fold (n ¼ 6 each group), analyzed when BDNF-expressing mice had lost 1.5 ± 0.22 g of weight and YFP mice gained 1.5 ± 0.56 g. We then used AGRP484 to drive a microRNA targeting BDNF ( Supplementary Fig. 3 online), which we inserted into the parent vector containing the constitutively expressing BDNF complementary DNA cassette. In other words, we made a single vector that expressed both BDNF under the control of a general constitutive promoter and a microRNA directed against BDNF under the control of the AGRP promoter (AGRP484-miR-Bdnf), a promoter that increases activity as the mice lose weight (Fig. 4a) . Because rAAVmediated BDNF expression leads to increased weight loss, we predicted that this physiological event would lead to increased AGRP promoter activity. That increased AGRP promoter activity, in turn, would drive the expression of the BDNF-specific microRNA in the same rAAV vector, resulting in a decrease in BDNF expression. Therefore, a balance between weight loss and weight gain would be achieved, thus preventing pathological cachexia from occurring, especially if the treated mouse's diet is not carefully controlled.
We used a mouse model of type 2 diabetes, db/db mice, and delayed the rAAV-mediated treatment until they were extremely obese and diabetic to investigate both the therapeutic efficacy as well as the autoregulatory efficiency of the dual-cassette vectors. When administered a control YFP-encoding virus, db/db mice continued to gain weight (Fig. 4b) . In contrast, when the mice were given a BDNFencoding vector together with a scrambled microRNA (BDNF-miRscr, targeting no known genes), their weight dropped precipitiously by 45.3% ± 3.6% in 3 weeks (Fig. 4b) . The weights of the mice receiving the BDNF plus the AGRP484-miR-Bdnf dropped markedly but began to level off and stabilized between 3 and 4 weeks after rAAV injection, with body weight maintained for the entire 11-week duration of the experiment, indicating efficient autoregulation of the BDNF transgene expression (Fig. 4b,c) . Both BDNF-miR-Bdnf-expressing and BDNFmiR-scr-expressing mice showed reduced food intake compared to YFP-expressing controls (Fig. 4d) , with increased rectal temperature indicating increased energy expenditure (data not shown). Moreover, gene therapy with the autoregulatory BDNF vector alleviated the obesity (Fig. 4e) , improved the insulin sensitivity and glucose tolerance (Fig. 4f,g ) and ameliorated the metabolic disturbances in db/db mice (Fig. 4h) . The profile of hypothalamic gene expression showed a similar pattern to that observed in wild-type mice but with a milder extent of changes that is likely to reflect the more controlled BDNF overexpression ( Supplementary Fig. 4a online) . Indeed, hypothalamic BDNF levels were 2055.6 ± 402.7 pg mg À1 in BDNF-miR-Bdnfexpressing mice, an 85% reduction from the 13323.3 ± 3899.8 pg mg À1 concentration in the BDNF-miR-Scr-expressing mice (P ¼ 0.023), and 100.7 ± 13.1 pg mg À1 in YFP-expressing mice. Gene therapy also improved the mobility of the extremely obese db/db mice and enhanced their physical activity and exploration behavior, as shown in an open-field test ( Supplementary Fig. 5 online) .
BDNF-induced weight loss is reversible by transgene knockout
To provide a further safeguard for this approach and the potential for a clinical rescue procedure, we wanted to use the loxP-Cre recombination system to generate a way to knock out the transgene, should the need arise because of adverse events 29 . We generated a rAAV vector with the BDNF transgene flanked by two loxP sites (flox-BDNF), which could be subsequently knocked out by a second viral vector delivering Cre recombinase. The rAAV vector encoding a GFP-Cre fusion protein has been shown to efficiently ablate loxP-modified genes in the brain, including the hypothalamus, with low toxicity 10, 30 . Bilateral injection of Cre vector alone did not influence body weight (data not shown) and did not cause toxicity ( Supplementary Fig. 2e and Supplementary Fig. 6a,b online) .
To establish an obesity model with greater clinical relevance, we fed C57BL/6 mice with the HFD for 10 weeks until their body 
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weight reached 40 g. The floxed BDNF vector was injected into the hypothalamus of the obese mice with nonfloxed YFP as a control (Fig. 5) . Flox-BDNF-expressing mice started to lose weight 7 d after injection and by 24 d had lost 29.3% ± 1.9% of their body weight, at which time the YFP-expressing mice had gained 9.0% ± 1.5% of their baseline weight (Fig. 5a ). Food consumption was slightly but significantly reduced in BDNF-expressing mice (BDNF-expressing mice, 2.06 ± 0.09 g per mouse per d, YFP-expressing mice, 2.44 ± 0.05 g per mouse per d, P ¼ 0.003). In addition, energy expenditure (kilocalories of heat produced) was markedly increased in BDNF-expressing mice during both the dark phase and light phase (Fig. 5b) . Physical activity was substantially increased in BDNF mice by 4.03 ± 0.28-fold compared to YFP mice in a 24 h period, particularly in the dark phase (Fig. 5c) . Notably, the respiratory exchange ratio was increased from 0.78 ± 0.03 in YFP-expressing mice to 0.87 ± 0.01 in BDNFexpressing mice (Fig. 5d) , suggesting increased carbohydrate oxidation as opposed to lipid oxidation, although both groups were fed with HFD. Obesity-associated glucose intolerance was alleviated by BDNF treatment 3 weeks after rAAV injection (Fig. 5e) . We then randomized flox-BDNF-expressing mice to groups receiving a second viral vector injection to the same site as the first surgery by receiving either GFP-Cre or empty viral vector as a control. All YFP-expressing mice received the GFP-Cre viral vector in the second surgery. GFP-Cre vector injection significantly suppressed BDNF mRNA and protein expression by 63.9% ± 9.0% and 71.6% ± 1.9%, respectively (P ¼ 0.002). Hypothalamic immunohistochemistry showed widespread GFP-Cre expression with less residual HA immunoreactivity, consistent with the B72% protein knockdown (Supplementary Fig. 6c ).
Moreover, HA-positive cells (those transduced by flox-BDNF vector) and GFP-positive cells (those transduced by GFP-Cre vector) were located in the same area, but no colocalization was observed, consistent with efficient Cre recombinase activity in co-transduced cells ( Supplementary Fig. 6c ). After the second surgery, YFP-expressing mice continued to gain weight, whereas flox-BDNF-expressing mice receiving empty vector in the second surgery continued to lose weight, although at a lower rate, and eventually the weight became stable (Fig. 5f ). Flox-BDNF-expressing mice receiving Cre virus reversed the progressive weight loss and commenced to regain weight gradually, although their weight remained substantially lower than the YFPexpressing obese mice (Fig. 5f) .
At the end of the study, approximately 4 months after the first surgery, both groups of BDNF-expressing mice showed markedly lower body mass index than the YFP-expressing controls (Fig. 5g) . Because body weight influences bone density and is considered as a risk factor for fracture 31 , we measured the bone mineral density of BDNF-expressing mice after considerable weight loss and found no difference in either the whole-body skeleton (excluding skull) or femur only (Fig. 5h) , indicating a lack of adverse effect on bones after BDNF-induced weight loss.
DISCUSSION
Clinical gene transfer should ideally include some regulatory control of therapeutic gene expression, particularly when constitutive expression of the transgene may be deleterious 32 . Several pharmacological gene regulation technologies have been developed. The Tet regulatory system, based on the use of small molecules such as tetracycline or doxycycline, is the most widely used 33, 34 . However, problems include the basal leakiness of the system and the potential immunogenicity of the foreign proteins, in addition to the need to administer a pharmacological agent with its own attendant risks. A dimerizer-regulated approach such as the rapamycin-FK506-binding protein system allows tight control in vivo and is less likely to be immunogenic, because the key components of this system are derived from human proteins. However, the size limitation of the cloned sequences in rAAV requires splitting the regulatory system into two separate vectors [35] [36] [37] . The use of two separate vectors is inefficient, owing to the need for double infection of the host cell. In addition, it remains a question whether the inducer drugs will be appropriate for the clinic.
Therefore, we constructed an autoregulatory system to control therapeutic gene expression, mimicking the body's natural molecular genetic feedback systems. Here we show the efficacy of such an approach using BDNF as the therapeutic gene, with weight loss and fat depletion as the physiological readout and an AGRP promoterdriven microRNA cassette as the regulatory agent. All of the components of this system can be packaged into a single rAAV vector for efficient delivery. To evaluate the regulation efficacy in vivo, we used a very high dose of the vector in db/db mice. The unchecked overexpression of BDNF led to marked weight loss, decrease of adiposity and improvement in serum metabolic parameters. However, the weight of mice receiving BDNF coupled with scrambled microRNA continued to drop (over 45% by 3 weeks after AAV injection) and showed no sign of stabilization, ultimately requiring us to euthanize the mice. Moreover, the BDNF-treated mice with severe weight loss and fat depletion, including the wild-type mice on NCD and the db/db mice, both treated with the nonregulated BDNF vectors, had a hyperactive phenotype, and their immunocompetence was compromised (data not shown). In contrast, the body weight of mice receiving an identical dose of the autoregulatory vector, in which the constitutive BDNF cassette was coupled with a physiologically responsive inhibitory microRNA construct, had a more gradual weight loss without any behavioral hyperactivity. The weight loss of these mice reached B20% by 3 weeks after injection and then plateaued throughout the entire 11-week duration of the experiment.
It is possible that by using experimental mice housed and fed in a tightly controlled laboratory environment, we can titrate the dose of vector to lead to the desirable weight loss without overshoot. However, in a clinical setting, diet and activity may vary unpredictably and from day to day. The efficacy of all current antiobesity approaches is compromised by an inability to mandate both a controlled lifestyle and energy-related activities, as well as by noncompliance to any given diet. Moreover, although repeat dosing is possible in gene therapy, every neurosurgical procedure carries with it some risk, and one of the major advantages of rAAV-mediated gene therapy is the potential for long-term, if not permanent, treatment of a disorder after a single intervention. Our approach enables a single dosing to which every obese individual could respond and yet adapts and autoregulates regardless of an individual's diet and lifestyle. The marked alleviation of obesity that we observed was associated with loss of liver steatosis, improvement in insulin sensitivity and glucose tolerance, and reversal of hyperleptinemia and lipid dyslipidemia. The approach we describe here could be potentially generalized to other molecular intervention studies in which expression of any given functional transgene is self-regulated by a microRNA driven by promoters activated, in turn, by the physiological changes induced by the transgene of interest.
Our data in two obesity and diabetes models show the potency and long-term efficacy of hypothalamic gene transfer of BDNF. Both suppression of food intake and heightening of energy expenditure contribute to the weight loss of db/db mice receiving BDNF, although the increase in energy expenditure of both basal metabolism and spontaneous activity seems more noteworthy, given that BDNFoverexpressing wild-type mice fed with either NCD or HFD (while weight remained normal) did not change food intake. Our data, though, are consistent with previous reports that have shown that BDNF has a more potent effect on appetite in obese mice. For example, chronic administration of BDNF protein substantially suppressed food intake in mice with DIO but not those fed on a standard diet 38 . In addition, acute or chronic administration of BDNF protein led to a marked decrease in food intake in genetic obesity models, including yellow agouti mice 38 and db/db mice 15 . This selective effect on appetite suppression in obese mice might best be explained by the basal pattern of anorexic and/or orexigenic signaling in the hypothalamus before BDNF treatment. The orexigenic Agrp and Npy mRNA levels were approximately sixfold and threefold higher in db/db mice than in wild-type mice, respectively, whereas the level of anorexic Pomc was 30% lower (Supplementary Fig. 4b ). The hyperphagia associated with these obesity models (genetic or diet-induced obesity) seems to reveal the appetite-suppressing effect of BDNF gene therapy that is not apparent in euphagic mice. We also showed that genes encoding proteins involved in energy expenditure, such as Ucps, were considerably upregulated in the liver and WAT of BDNF-expressing mice. Moreover, the comprehensive analysis of gene expression in hypothalamus, liver and fat in this study provides further insights into the potential mechanisms underlying the hypothalamic BDNF regulation of energy balance. For example hypothalamic Crh expression was consistently increased in all of the models we used and, accompanied by the increase in physical activity, suggests a potential pathway of BDNF regulation of the hypothalamus-pituitary-adrenal axis, food intake and energy expenditure 39, 40 . In addition, WAT seems to be a primary peripheral organ responsive to hypothalamic BDNF, with not only the display of much smaller adipocytes but also substantial differences in the expression profile of adipokines and genes involved in lipid metabolism and mitochondrion activity. The WAT reduction was primarily due to a reduction in cell size without much impact on cellular viability, as shown by lack of adipocyte apoptosis (data not shown) and reversible weight gain when the BDNF transgene was knocked out by expression of Cre.
In summary, we have developed several strategies to achieve potent and safe gene therapy for obesity and related metabolic syndromes with AAV-BDNF vectors, including dose adjustment, an autoregulatory negative feedback system using RNAi coupled to transgeneinduced physiological changes and, finally, a definitive knockout via delivery of a second, rescue vector. Long-term observation of mice receiving these therapeutic vectors in both DIO and diabetic genetic models showed improved general health, metabolic parameters and physical activity with no adverse impact on bone density or disturbance in circadian rhythm or home cage activity. The combination of these strategies will further strengthen the safety of this gene therapy approach and provide potent therapeutics for morbid obesity.
METHODS
Mice. We used male 8-week-old C57BL/6 mice (from Charles River) and male 4-month-old db/db mice (from Jackson Laboratories). All use of animals was approved by and in accordance with the Ohio State University Animal Care and Use Committee.
Recombinant adeno-associated viral vector construction and packaging. The rAAV plasmid contains a vector expression cassette consisting of the cytomegalovirus enhancer, the chicken b-actin (CBA) promoter, the woodchuck posttranscriptional regulatory element (WPRE) and bovine growth hormone polyadenosine flanked by AAV inverted terminal repeats. We fused human BDNF cDNA to the HA tag at the 5¢ terminus and then inserted it into the multiple cloning sites between the CBA promoter and the WPRE sequence. We cloned the genes encoding EGFP or destabilized YFP into the rAAV plasmid as controls. We packaged and purified rAAV serotype 1 vectors as described elsewhere 5, 6 .
Adeno-associated virus-mediated brain-derived neurotrophic factor overexpression in mice kept on standard diet. We randomly assigned 23 C57BL/6 mice, male, 8 weeks of age, to groups receiving rAAV-BDNF (n ¼ 13) or rAAV-GFP (n ¼ 10). We anesthetized the mice with a single dose of ketamine and xylazine (100 mg kg À1 and 20 mg kg À1 , respectively, intraperitoneally) and secured them via ear bars and an incisor bar on a Kopf stereotaxic frame. We made a midline incision through the scalp to reveal the skull and drilled two small holes into the skull with a dental drill above the injection sites (1.2 mm posterior to the bregma, 0.5 mm lateral to the midline, 6.2 mm dorsal to the bregma). We injected rAAV vectors (3 Â 10 9 genomic particles per site) bilaterally into the hypothalamus at a rate of 0.1 ml min À1 with a 10-ml Hamilton syringe attached to a Micro4 Micro Syringe Pump Controller (World Precision Instruments). At the end of infusion, we slowly raised the syringe from the brain and sutured the scalp. We placed the mice back into a clean cage and carefully monitored them after surgery until recovery from anesthesia. We fed mice with normal chow diet (NCD, 11% fat, 28% protein, 61% carbohydrate, caloric density 3.4 kcal g À1 , Research Diets).
High-fat diet-induced obesity model. We randomly assigned 24 male C57BL/ 6 mice, 18 weeks of age, to groups receiving rAAV-BDNF (n ¼ 13) or rAAV-YFP (n ¼ 11). We injected rAAV vectors (2 Â 10 9 genomic particles per site) bilaterally into the hypothalamus as described above. We switched the diet to high-fat diet (HFD, 45% fat, caloric density 4.73 kcal g À1 , Research Diets) on day 10 after rAAV injection and fed the mice with HFD until the end of the study (72 d after injection).
microRNA vector construction and adeno-associated vector production. We used microRNA to target BDNF. We cloned two targeting sequences in the BDNF coding region into the Block-iT PolII miR RNAi expression vector (pcDNA6.2-Gw/miR, Invitrogen). In in vitro experiments, both miR constructs inhibited BDNF expression when co-transfected with a BDNF expression plasmid, as confirmed by quantitative PCR and ELISA for BDNF (BDNF Emax ImmunoAssay System, Promega). We chose the miR-Bdnf construct with mature microRNA sequence: 5¢-AATACTGTCACACACGCTCAG-3¢) for in vivo experiments. We subcloned this miR-Bdnf and a scrambled microRNA (miR-scr, with the scrambled sequence targeting no known gene, Invitrogen) in to the rAAV plasmid driven by CBA promoter as described above.
body weight and food consumptions periodically until the end of the experiment (79 d after injection).
Knockdown of transgene expression by Cre-loxP recombination. We generated the DIO model by feeding mice with HFD for 10 weeks until the body weight reached 40 g. We randomly assigned the obese mice to groups receiving rAAV flox-BDNF or rAAV-YFP. We injected rAAV vectors bilaterally to the hypothalamus as described above (1.0 Â 10 10 genomic particles per site). We monitored body weight every 5-7 d and recorded the food intake. One month after first surgery, we split the flox-BDNF-expressing mice into two groups receiving rAAV-GFP-Cre or empty rAAV as a control. We injected all YFPexpressing mice with rAAV-GFP-Cre. We performed the second surgery with the same procedure as the first surgery. We kept the mice on HFD until the end of the study (4 months after the first surgery).
Statistical analyses.
Values are expressed as means ± s.e.m. For body weight, insulin tolerance and glucose tolerance, we determined the overall significance by one-way repeated measure analysis of variance. We used one-way analysis of variance to analyze serum biomarker measurements, liver weight and adipose tissue weight. We used multivariate analysis of variance to analyze quantitative RT-PCR data.
Additional methods. Detailed methodology is described in the Supplementary Methods online.
Note: Supplementary information is available on the Nature Medicine website.
